Key facts
- Neuroceuticals’s last known valuation is $13.1M (Nov 2018).
- It has raised $4.6M.
- Notable investors include Mizuho Capital, Sasaki Food, Astem, Kaga Electronics, Kyushu University — 8 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 8 names
- ·Watchlist + deal alerts for Neuroceuticals
- ·The full record, as it builds
Funding rounds
No funding rounds for Neuroceuticals are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Neuroceuticals
Developer of a medical device incubator and accelerator intended to support and advance medical start-up companies. The company offers mentorship, funding support, and access to research and clinical expertise, enabling medical start-ups to develop and commercialize innovative healthcare technologies efficiently.
- Sector
- Healthcare
- HQ
- Tokyo, Japan
- Founded
- 2009
- Employees
- 30
- Website
- nci-md.com/
- Ownership
- Privately Held (backing)
Neuroceuticals doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Neuroceuticals shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Neuroceuticals in its N-PORT filings yet. We sweep new filings monthly.